Patent · US Active

Treatment of celiac disease with IgA

US8119104B2 · kind B2 · utility

3Cited by

6References

13Claims

0Family size

Assignee

Michael R. Simon · US

Inventors

Michael R. Simon · Ann Arbor, US
Mark Andrew Kroenke · Newbury Park, US

Key dates

Filing date	Jan 25, 2011
Grant date	Feb 21, 2012
Priority date	—
Expiry date	Jan 25, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/52
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A process for inhibiting symptoms of a subject with celiac disease is provided that includes administration of monoclonal-, or polyclonal-, monomeric, dimeric, or polymeric IgA. Joining secretory component to the IgA limits oral administration degradation. Formulating agents are mixed with the monomeric, dimeric, or polymeric IgA to yield a dosing form of a capsule, tablet, and a suppository. The therapeutic is amenable to enrobement directly through microencapsulation or the dosing form is coated with an enteric coating.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.